NFE2L2 and diabetic kidney disease: Bardoxolone methyl, an activator of Nrf2, has undergone initial testing in a phase 2 clinical trial involving patients with DKD (BEAM study), demonstrating a significant improvement in eGFR after 52 weeks of treatment [246].